| Stephen Tangulie Tonsong, PHARMACIST | |
|
3710 57th Ave, Kenosha, WI 53144-4820 | |
| (262) 652-1474 | |
| Not Available |
| Full Name | Stephen Tangulie Tonsong |
|---|---|
| Gender | Male |
| Speciality | Pharmacy - Community/retail Pharmacy |
| Location | 3710 57th Ave, Kenosha, Wisconsin |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609463546 | NPI | - | NPPES |
| 20215-40 | Other | WI | PHARMACIST |
| 1965179 | Other | WI | PHARMACIST |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 20215-40 (Wisconsin) | Secondary |
| 3336C0003X | Pharmacy - Community/retail Pharmacy | 20215-40 (Wisconsin) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Stephen Tangulie Tonsong, PHARMACIST 3710 57th Ave, Kenosha, WI 53144-4820 Ph: (262) 652-1474 | Stephen Tangulie Tonsong, PHARMACIST 3710 57th Ave, Kenosha, WI 53144-4820 Ph: (262) 652-1474 |
News Archive
A group of scientists led by Professor Xavier Pares of the Department of Biochemistry and Molecular Biology at Universitat Autonoma de Barcelona, has published a research on AKR1B10, an enzyme that is detected in large quantities only in lung cancers, particularly those caused by smoking.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
CANCER RESEARCH UK Cancer Research UK scientists have discovered why a sub group of oestrogen-receptor-negative breast cancer patients could benefit from prostate cancer treatments which target the cell's androgen receptor - a key driver of prostate cancer, according to research published in The EMBO Journal today.
Studies by researchers at Wake Forest University School of Medicine have shown that blocking the NMDA receptor in immature rats leads to profound, rapid brain injury and disruption of auditory function as the animals mature.
› Verified 4 days ago